Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Biocatalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN119823959B reveals novel imine reductase mutants for high-purity chiral amine synthesis, offering significant cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN101392225A reveals a recombinant yeast route for high-purity (S)-CHBE, offering significant cost reduction in API manufacturing and robust supply chain scalability.
Patent CN105316250A reveals Empedobacter brevis strain for high-purity chiral alcohols. Offers cost reduction and scalable supply for pharmaceutical intermediates.
Patent CN1940079A details a novel baker's yeast reduction for synthesizing (2S,3S)-2-benzoyl aminomethyl-3-hydroxy-butyrate, a critical 4-AA precursor, offering mild conditions and high optical purity.
Patent CN100376681C details a microbial asymmetric reduction method for (R)-mandelic acid using Saccharomyces cerevisiae, offering a green, cost-effective alternative to traditional chemical resolution for pharmaceutical manufacturing.
Patent CN115109759B reveals novel LsCR mutants for chiral alcohol synthesis. Achieve superior stability and yield for reliable pharmaceutical intermediate supply chains.
Patent CN103255183B details enzymatic asymmetric reduction for high-purity intermediates. Offers significant cost reduction and supply chain reliability for statin synthesis.
Patent CN107384982A reveals enzymatic route for Evogliptin. Offers high purity and scalable manufacturing for global pharmaceutical supply chains.
Patent CN1119332C details a novel asymmetric hydrogenation route for azepine intermediates, offering cost-effective and scalable production for kinase inhibitors like Balanol.
Patent CN104099305A reveals stable CgKR1 mutants for Clopidogrel intermediates. Enhances purity and supply chain reliability for global pharmaceutical manufacturing.
Patent CN102994403A details a novel whole-cell biocatalytic route for (R)-2-hydroxy-4-phenylbutyric acid ethyl ester, offering superior stereoselectivity and cost efficiency for pharmaceutical manufacturing.
Novel Bacillus megaterium strain enables high-purity R-4-chloro-3-hydroxybutyrate production with reduced costs and environmental impact.
Patent CN100385007C details a microbial method for (R)-mandelic acid using Brevibacterium flavum, offering high optical purity and scalable biocatalysis for pharma intermediates.
Advanced patent CN110590606A details efficient asymmetric hydrogenation and enzymatic reduction for high-purity pharmaceutical intermediates, ensuring cost-effective and scalable supply chain solutions.
Patent CN1491951A reveals novel asymmetric hydrogenation and microbial routes for high-purity azepine intermediates, offering significant cost reduction in pharmaceutical manufacturing.
Discover advanced catalytic methods for pyrimidylcyclopentane intermediates. Enhance purity and reduce costs in AKT inhibitor manufacturing with our scalable solutions.